Summary
This 2018 Nature Medicine publication presents findings from a multicentre clinical trial comparing immunotherapy-based approaches with standard tyrosine kinase inhibitor therapy in renal cell carcinoma. The study integrated clinical efficacy data with molecular profiling to identify predictive biomarkers of response to atezolizumab monotherapy, the combination of atezolizumab and bevacizumab, and sunitinib treatment. The work contributes to precision oncology by correlating immune checkpoint inhibitor response with underlying molecular characteristics in advanced renal cancer.
UK applicability
The findings are directly applicable to UK oncology practice, as atezolizumab and bevacizumab are used in the UK National Health Service for renal cell carcinoma treatment. The identified molecular predictors may inform patient stratification and treatment selection decisions in British cancer centres.
Key measures
Objective response rates, progression-free survival, overall survival, molecular biomarkers predictive of treatment response
Outcomes reported
The study evaluated clinical activity, response rates, and molecular biomarkers associated with atezolizumab monotherapy, atezolizumab plus bevacizumab combination, and sunitinib in patients with renal cell carcinoma. Molecular correlates of treatment response were identified and analysed.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.